Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
24.16 USD | -2.40% | -8.05% | -18.33% |
05-10 | Morgan Stanley Adjusts Price Target on Mirum Pharmaceuticals to $53 From $57, Keeps Overweight Rating | MT |
05-08 | Transcript : Mirum Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 08, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.33% | 1.17B | |
+42.58% | 58.71B | |
-2.96% | 41.31B | |
+36.36% | 39.2B | |
-10.22% | 27.4B | |
+10.46% | 26.55B | |
-22.27% | 18.98B | |
+1.02% | 12.51B | |
+26.59% | 12.08B | |
+21.20% | 11.94B |
- Stock Market
- Equities
- MIRM Stock
- News Mirum Pharmaceuticals, Inc.
- Mirum Pharmaceuticals Says US FDA Extends Supplemental NDA Review for Livmarli to March 13; Shares Fall After Hours